Search Results 721-730 of 18306 for prostate cancer

  1. Breast cancer - Doctors and departments - Mayo Clinic

    for prostate cancer, Radiation therapy for prostate cancer, Intensity ... cancer, Liver cancer, Esophageal cancer, Rectal cancer, Bone metastasis. Show ...

  2. Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer - Mayo Clinic

    ... prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made ...

  3. Breast cancer - Doctors and departments - Mayo Clinic

    for prostate cancer, Radiation therapy for prostate cancer, Intensity ... cancer, Liver cancer, Esophageal cancer, Rectal cancer, Bone metastasis. Show ...

  4. A Study Of Serum Vitamin D Levels For Nigerian And USA Black Prostate Cancer Patients - Mayo Clinic

    The purpose of this study is to compare the immunological effects of vitamin D deficiency and its correction in Black/West African prostate cancer (CaP) ...

  5. Clinical trials - Oncology (Medical)

    ... prostate cancer. The objectives are to describe the practice patterns of therapeutic agents for treatment of advanced prostate cancer internationally; to ...

  6. Clinical trials - Oncology (Medical)

    ... prostate cancer. The objectives are to describe the practice patterns of therapeutic agents for treatment of advanced prostate cancer internationally; to ...

  7. Breast cancer - Doctors and departments - Mayo Clinic

    cancer, Breast cancer, Head and neck cancer, Prostate cancer, Bladder cancer, Testicular cancer. Show more areas of focus for Carlos E. Vargas, M.D. ...

  8. Study Of PSMA-targeted Therapy And Androgen Receptor Suppression In Low-volume Metastatic ProstatE Cancer: SPARKLE Trial - Mayo Clinic

    Study Of PSMA-targeted Therapy And Androgen Receptor Suppression In Low-volume Metastatic ProstatE Cancer: SPARKLE Trial · Share · Facebook · Twitter.

  9. A Study Of Single Patient Investigational Drug CPI-613 For Use In Treatment-Refractory, Metastatic Prostate Cancer - Mayo Clinic

    About this study. This is a single patient study of an investigational drug CPI-613 for treatment of metastatic prostate cancer. Participation eligibility.

  10. Efficacy Of [18F]PSMA-1007 PET/CT In Patients With Biochemial Recurrent Prostate Cancer - Mayo Clinic

    This study evaluates the diagnostic performance and safety of [18F]PSMA-1007 PET/CT imaging in patients with suspected recurrence of prostate cancer after ...